VishnuGarlaMD

Diabetes, Lipid Metabolism, Thyroid

Physician

Dr. Garla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2500 North State Street
Division Of Endocrinology
Jackson, MS 39216
Phone+1 601-984-5525

Fax+1 601-984-5769

University of Mississippi Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2013 - 2015
Marshall University School of MedicineResidency, Internal Medicine/Pediatrics, 2009 - 2013
J.J.M. Medical CollegeClass of 2004

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score Start of enrollment: 2021 Nov 09
Recruiting
Phase 2
Roles: Contact, Principal Investigator

PubMed

119 citations
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado, Jan Oscarsson, Samvel B. Gasparyan
The Lancet. Diabetes & Endocrinology. 2021-09-01
7 citations
SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
Vishnu Garla, Javed Butler, Lillian F. Lien
Current Cardiology Reports. 2021-05-07
3 citations
Epidemiology of cannabis use and associated outcomes among kidney transplant recipients: A meta-analysis.
Pradeep Vaitla, Charat Thongprayoon, Panupong Hansrivijit, Swetha R Kanduri, Karthik Kovvuru
Journal of Evidence-Based Medicine. 2021-05-01

University of Mississippi Medical Center: 1st Quarter Grants and Awards Top $31 MillionNovember 2nd, 2021
FREEDOM: Researchers Study Impact of Food Delivery, Coaching, Telemonitoring on DiabetesSeptember 11th, 2023